Without intervention, nearly half the adults in the US are expected to be obese by 2030 4
Some emerging research has explored potential immunomodulatory effects of GLP-1 receptor agonists, with preliminary studies suggesting possible anti-inflammatory properties that may benefit patients with chronic low-grade inflammation associated with obesity and metabolic syndrome
Injectable use: Not FDA-approved
Our pharmacists can customize strengths, adjust ingredients, and prepare medications in alternative dosage forms to better support individual treatment plans
During US GLP-1 shortages a few years ago, pharmacies were also permitted to produce compounded semaglutide and tirzepatide, but the FDA says that exemption ended once supplies recovered in early 2025
4c), equivalent to the anti-PCSK9 antibody Ab#2.1 (Supplementary Fig